Axial Therapeutics has a total of 28 patents globally, out of which 7 have been granted. Of these 28 patents, more than 92% patents are active. The United States of America is where Axial Therapeutics has filed the maximum number of patents, followed by Australia and Canada. Parallelly, the United States of America seems to be the main focused R&D centre of Axial Therapeutics.
Axial Therapeutics was founded in the year 2016 by David Donabedian, PhD, Jeffrey Young and Michelle Dipp. The company is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System.
Do read about some of the most popular patents of Axial Therapeutics which have been covered by us in this article and also you can find Axial Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Axial Therapeutics patent portfolio.
How many patents does Axial Therapeutics have?
Axial Therapeutics has a total of 28 patents globally. These patents belong to 7 unique patent families. Out of 28 patents, 26 patents are active.
How Many Patents did Axial Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Axial Therapeutics Applications Filed | Axial Therapeutics Patents Granted |
| 2022 | 3 | 3 |
| 2021 | 13 | 3 |
| 2020 | 1 | 1 |
| 2018 | 11 | – |
How many Axial Therapeutics patents are Alive/Dead?
How Many Patents did Axial Therapeutics File in Different Countries?
Where are Research Centres of Axial Therapeutics Patents Located?
The research Centre of all Axial Therapeutics Patents is the United States of America.
What Percentage of Axial Therapeutics US Patent Applications were Granted?
Axial Therapeutics (Excluding its subsidiaries) has filed 5 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 3 have been granted leading to a grant rate of 100.0%.
Below are the key stats of Axial Therapeutics patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Axial Therapeutics?
| Law Firm | Total Applications | Success Rate |
| Knobbe Martens Olson & Bear Llp | 3 | 100.00% |
| Wolf Greenfield & Sacks Pc | 2 | 100.00% |
List of Axial Therapeutics Patents
| Axial Therapeutics Patents | Title |
| HK40075263A | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders |
| AU2021280287A1 | TLR2 modulator compounds, pharmaceutical compositions and uses thereof |
| BR112022024071A2 | TLR2 MODULATOR compounds, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
| US11505528B2 | Inhibitors of microbially induced amyloid |
| EP4087560A2 | Inhibitors of microbially induced amyloid |
| AU2021206267A1 | Inhibitors of microbially induced amyloid |
| NZ758692B | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders |
| WO2022098879A1 | Sustained release solid dosage forms for modulating the colonic microbiome |
| US20220133634A1 | Sustained release solid dosage forms for modulating the colonic microbiome |
| NZ785988A | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders |
| US11278498B2 | Sustained release solid dosage forms for modulating the colonic microbiome |
| US20220040145A1 | Inhibitors of microbially induced amyloid |
| AU2022200220A1 | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders |
| WO2021242923A1 | Tlr2 modulator compounds, pharmaceutical compositions and uses thereof |
| CA3177546A1 | Tlr2 modulator compounds, pharmaceutical compositions and uses thereof |
| NZ794925A | TLR2 modulator compounds, pharmaceutical compositions and uses thereof |
| US11147792B2 | Inhibitors of microbially induced amyloid |
| US20210317508A1 | Methods and apparatus for determining risk of autism spectrum disorder |
| AU2021206871B2 | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders |
| WO2021142333A3 | Inhibitors of microbially induced amyloid |
| CA3167292A1 | Inhibitors of microbially induced amyloid |
| NZ791097A | Inhibitors of microbially induced amyloid |
| EP3664822A4 | Inhibitors of microbially induced amyloid |
| AU2018243836B9 | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders |
| EP3600349A4 | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders |
| US10617718B2 | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders |
| CA3108484A1 | Inhibitors of microbially induced amyloid |
| CA3095724A1 | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders |